ARCH Venture Fund XII, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1906837. 7 Form 4 filings on record with FilingPulse; latest filed 2026-05-04.

Transaction summary — filings shown

Covers all 7 filings on record, filed 2024-02-20 to 2026-05-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Metsera, Inc. (MTSR)Director, 10% owner22 legs · 2,222,222 sh · $39,999,9969
Prime Medicine, Inc. (PRME)10% owner22 legs · 6,230,300 sh · $29,999,990
Seaport Therapeutics, Inc. (SPTX)10% owner11 leg · 1,100,000 sh · $19,800,0004
Neumora Therapeutics, Inc. (NMRA)10% owner11 leg · 1,915,700 sh · $4,999,977
Rapport Therapeutics, Inc. (RAPP)10% owner13

Form 4 filings — ARCH Venture Fund XII, L.P.

FiledFormIssuerReported transactionsSource
2026-05-044Seaport Therapeutics, Inc. (SPTX)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0EDGAR
2025-11-144Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT
Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680EDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON
Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-014Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P.
Purchase (P): 3,030,300 @ $3.30EDGAR
2025-02-034Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT
Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 moreEDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0EDGAR
2024-02-204Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P.
Purchase (P): 3,200,000 @ $6.25EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1906837 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →